- Home
- ZIMV vs CELC Comparison
ZIMV vs CELC Comparison
Compare ZIMV & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIMV
- CELC
- Stock Information
- Founded
- ZIMV 2021
- CELC 2011
- Country
- ZIMV United States
- CELC United States
- Employees
- ZIMV N/A
- CELC N/A
- Industry
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CELC Medical Specialities
- Sector
- ZIMV Health Care
- CELC Health Care
- Exchange
- ZIMV Nasdaq
- CELC Nasdaq
- Market Cap
- ZIMV 367.9M
- CELC 440.7M
- IPO Year
- ZIMV N/A
- CELC 2017
- Fundamental
- Price
- ZIMV $13.31
- CELC $13.15
- Analyst Decision
- ZIMV Buy
- CELC Strong Buy
- Analyst Count
- ZIMV 2
- CELC 6
- Target Price
- ZIMV $19.50
- CELC $30.17
- AVG Volume (30 Days)
- ZIMV 116.1K
- CELC 184.2K
- Earning Date
- ZIMV 02-26-2025
- CELC 03-26-2025
- Dividend Yield
- ZIMV N/A
- CELC N/A
- EPS Growth
- ZIMV N/A
- CELC N/A
- EPS
- ZIMV N/A
- CELC N/A
- Revenue
- ZIMV $451,294,000.00
- CELC N/A
- Revenue This Year
- ZIMV $0.74
- CELC N/A
- Revenue Next Year
- ZIMV $1.37
- CELC N/A
- P/E Ratio
- ZIMV N/A
- CELC N/A
- Revenue Growth
- ZIMV 267.15
- CELC N/A
- 52 Week Low
- ZIMV $12.84
- CELC $10.35
- 52 Week High
- ZIMV $22.40
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- ZIMV 41.86
- CELC 60.85
- Support Level
- ZIMV $12.84
- CELC $12.55
- Resistance Level
- ZIMV $13.46
- CELC $13.25
- Average True Range (ATR)
- ZIMV 0.31
- CELC 0.68
- MACD
- ZIMV -0.03
- CELC 0.14
- Stochastic Oscillator
- ZIMV 33.87
- CELC 85.79
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.